Seegene Inc
Seegene Inc is a South Korean biotechnology company that develops and commercializes molecular diagnostic solutions, primarily for infectious diseases and cancer, generating revenue through product sales and research collaborations.
Business. Seegene Inc (096530.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Seegene Inc (096530.KQ) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Seegene Inc maintains a strong liquidity position, with a current ratio of 4.68 and cash and equivalents amounting to KRW 225.57 billion, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio of 0.13 suggests a conservative capital structure, with long-term debt at KRW 129.93 billion and total equity at KRW 1,015.45 billion.
Profitability metrics show a return on equity (ROE) of 4.75% and a return on assets (ROA) of 3.91%, which are in line with industry norms for biotechnology firms. The company's operating income of KRW 26.15 billion and net income of KRW 48.27 billion reflect a healthy margin, supported by a gross profit of KRW 303.86 billion.
Geographically, Seegene's revenue is concentrated in South Korea, with a significant portion derived from domestic sales. The company's exposure to international markets is limited, which may pose a risk in the event of domestic economic downturns or regulatory changes.
The company's growth trajectory is positive, with a revenue of KRW 474.23 billion in the latest reporting period. Analysts project a mean price target of KRW 39,500, with a median of KRW 39,500, indicating a generally optimistic outlook. The company's capital expenditure of KRW -40.47 billion suggests a focus on cost management and operational efficiency.
Risk factors for Seegene include potential regulatory changes in the biotechnology sector and the competitive landscape in molecular diagnostics. The company's dilution risk is currently low, with no immediate filing-based flags detected. However, the potential for future dilution remains a consideration, particularly if the company pursues expansion through equity financing.
Recent events include the release of the latest financial snapshot, which provides updated figures on revenue, profitability, and liquidity. The company has not disclosed any major new product launches or strategic partnerships in the most recent filings, but ongoing research and development efforts are expected to drive future growth.
- Seegene Inc maintains a strong liquidity position with a current ratio of 4.68 and significant cash reserves.
- The company's profitability metrics, including ROE of 4.75% and ROA of 3.91%, are in line with industry norms.
- Revenue is concentrated in South Korea, which may pose a risk in the event of domestic economic or regulatory changes.
- Analysts project a mean price target of KRW 39,500, indicating a generally optimistic outlook for the company.
- The company's capital expenditure is negative, suggesting a focus on cost management and operational efficiency.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1 116,18 |
| Revenue | —no estimate | —no estimate | 529,0B KRW |
| Operating income | —no estimate | —no estimate | 52,3B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Seegene Inc Market data — financials · 2026-05-26
- Seegene Inc Market data — analyst estimates · 2026-05-26
- Seegene Inc Market data — ESG · 2026-05-26
Ownership & reference
Leadership
- Jin Su ChoiPresident, Director